Search results
Breakthrough Study Reveals Somavedic Device's Potential Impact on Wet AMD Patients
Yucaipa News Mirror· 2 days agoThe study enrolled patients with newly diagnosed wet AMD and active choroidal neovascularization (CNV), where anti-VEGF therapy was indicated.
Byooviz dosage: Form, strength, when to use, and more
Medical News Today· 7 days agoByooviz (ranibizumab-nuna) is a brand-name drug prescribed for certain eye conditions in adults. It...
Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy
Morningstar· 7 days ago(NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for < ...
2 Small-Cap Growth Stocks With Room to Run
Motley Fool via Yahoo Finance· 18 hours agoCurrently, Wall Street analysts believe the company's shares could be undervalued by as much as 210%. The reason? Ocular is developing a novel therapy...
Health Care Roundup: Market Talk
The Wall Street Journal· 2 days agoMoreover, its planned launch of aflibercept—for patients living with wet macular degeneration—could be a potentially significant biosimilar ...
Local women with low vision gather to share experiences, advances in tech
telegraphherald.com· 4 days agoGathered around a long table in the back of Caroline’s Restaurant in Dubuque, a group of women...
PharmAbcine's U.S. Subsidiary, Wincal Biopharm, to Present Preclinical Data from its Proprietary OPC...
Morningstar· 2 days agoPreclinical data from the next generation eyedrop platform to be unveiled for the first time at ARVO 2024DAEJEON, South Korea, April 22, 2024 /PRNewswire/ -- PharmAbcine, Inc. ("PharmAbcine" or the "Company") (KOSDAQ: 208340), a clinical-stage public
Cantor Fitzgerald Equities Analysts Increase Earnings Estimates for Regeneron Pharmaceuticals, Inc....
ETF DAILY NEWS· 2 days agoRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) – Analysts at Cantor Fitzgerald boosted their FY2024 earnings estimates for Regeneron Pharmaceuticals in a research report issued ...
Ocugen (NASDAQ:OCGN) Given New $5.00 Price Target at Chardan Capital
ETF DAILY NEWS· 3 days agoOcugen (NASDAQ:OCGN – Get Free Report) had its price objective increased by stock analysts at Chardan Capital from $4.00 to $5.00 in a research report issued on Monday, Benzinga reports. Chardan ...
StockNews.com Downgrades Regeneron Pharmaceuticals (NASDAQ:REGN) to Buy
ETF DAILY NEWS· 3 days agoSeveral other research analysts have also weighed in on REGN. Truist Financial restated a “buy” rating and set a $1,135.00 price objective on shares of Regeneron Pharmaceuticals in a research ...
